Comparison of three assays for quantifying S-100B in serum

Clinica Chimica Acta

Volumn 412, Issue 23-24, 2011, Pages 2122-2127

  Erickson, J Alan ^a   Grenache, David G ^a,b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Brain injury; ELISA; Melanoma; S 100B

Indexed keywords

PROTEIN S100B;

ACCURACY; ARTICLE; CALIBRATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MALE; NONPARAMETRIC TEST; PRIORITY JOURNAL; REFERENCE VALUE; SEX DIFFERENCE;

BRAIN INJURIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIMIT OF DETECTION; MELANOMA; MONITORING, PHYSIOLOGIC; NERVE GROWTH FACTORS; REPRODUCIBILITY OF RESULTS; S100 PROTEINS;

EID: 80053622428     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.07.020     Document Type: Article

References (26)

1. Raabe A., Grolms C., Sorge O., Zimmermann M., Seifert V. Serum S-100B protein in severe head injury. Neurosurgery 1999, 45:477-483.
2. Boni R., Burg G., Doguoglu A., et al. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions. Br J Dermatol 1997, 137:39-43.
3. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001, 33:637-668.
4. Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999, 1450:191-231.
5. Andres R., Mayordomo J.I., Zaballos P., et al. Prognostic value of serum S-100B in malignant melanoma. Tumori 2004, 90:607-610.
6. Hamberg A.P., Korse C.M., Bonfrer J.M., de Gast G.C. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res 2003, 13:45-49.
7. Smit L.H., Nieweg O.E., Mooi W.J., et al. Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma. Anticancer Res 2008, 28:2297-2302.
8. Korfias S., Stranjalis G., Papadimitriou A., et al. Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts. Curr Med Chem 2006, 13:3719-3731.
9. Stroick M., Fatar M., Ragoschke-Schumm A., Fassbender K., Bertsch T., Hennerici M.G. Protein S-100B-a prognostic marker for cerebral damage. Curr Med Chem 2006, 13:3053-3060.
10. Bertsch T., Casarin W., Kretschmar M., et al. Protein S-100B: a serum marker for ischemic and infectious injury of cerebral tissue. Clin Chem Lab Med 2001, 39:319-323.
11. Biberthaler P., Mussack T., Wiedemann E., et al. Evaluation of S-100b as a specific marker for neuronal damage due to minor head trauma. World J Surg 2001, 25:93-97.
12. Chen D.Q., Zhu L.L. Dynamic change of serum protein S100b and its clinical significance in patients with traumatic brain injury. Chin J Traumatol 2005, 8:245-248.
13. da Rocha A.B., Schneider R.F., de Freitas G.R., et al. Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males. Clin Chem Lab Med 2006, 44:1234-1242.
14. Korfias S., Stranjalis G., Boviatsis E., et al. Serum S-100B protein monitoring in patients with severe traumatic brain injury. Intensive Care Med 2007, 33:255-260.
15. Stranjalis G., Korfias S., Psachoulia C., Kouyialis A., Sakas D.E., Mendelow A.D. The prognostic value of serum S-100B protein in spontaneous subarachnoid haemorrhage. Acta Neurochir (Wien) 2007, 149:231-237. [discussion 237-238].
16. Wiesmann M., Missler U., Hagenstrom H., Gottmann D. S-100 protein plasma levels after aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien) 1997, 139:1155-1160.
17. Reynolds M.A., Kirchick H.J., Dahlen J.R., et al. Early biomarkers of stroke. Clin Chem 2003, 49:1733-1739.
18. Missler U., Wiesmann M., Friedrich C., Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997, 28:1956-1960.
19. Prohl J., Rother J., Kluge S., et al. Prediction of short-term and long-term outcomes after cardiac arrest: a prospective multivariate approach combining biochemical, clinical, electrophysiological, and neuropsychological investigations. Crit Care Med 2007, 35:1230-1237.
20. Nakamura K., Ueno T., Yamamoto H., Iguro Y., Yamada K., Sakata R. Relationship between cerebral injury and inflammatory responses in patients undergoing cardiac surgery with cardiopulmonary bypass. Cytokine 2005, 29:95-104.
21. Smit L.H., Korse C.M., Bonfrer J.M. Comparison of four different assays for determination of serum S-100B. Int J Biol Markers 2005, 20:34-42.
22. Hallen M., Carlhed R., Karlsson M., Hallgren T., Bergenheim M. A comparison of two different assays for determining S-100B in serum and urine. Clin Chem Lab Med 2008, 46:1025-1029.
23. DiaSorin, Inc. Sangtec® 100 ELISA, instruction manual March 2004, Revision.
24. Stigbrand T., Nyberg L., Ullen A., Haglid K., Sandstrom E., Brundell J. A new specific method for measuring S-100B in serum. Int J Biol Markers 2000, 15:33-40.
25. Fujirebio Diagnostics AB CanAg® S100 EIA, instructions for use October 2006, Revision.
26. Yanaihara Institute, Inc. YK150 Human S-100 β ELISA, kit insert May 2007, Revision.